Filtered By:
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 220 results found since Jan 2013.
Statins and Cancer
Numerous reports have been published in the medical literature suggesting that the use of statins may be associated with a reduced risk of certain types of cancer. Numerous other reports have said, in contrast, that statins have no effect on cancer risk. Given these conflicting medical studies, what do the experts currently say about statins and cancer?...Read Full Post
Source: About.com Heart Disease - April 12, 2013 Category: Cardiology Source Type: blogs
I am really sorry to be a downer . . .
but, the new BMJ demands that I bum you out.Britain's Chief Medical Officer -- kind of like our Surgeon General, except that she actually gets out of bed in the morning -- issues a report on antibiotic resistance. Yes, I write about this from time to time and hear and there you will hear someone cry with alarm, and yet nobody does a damn thing about it.It seems that after the Good Lord intelligently designed microorganisms that can kill us and make us sick, He forgot to prevent them from evolving. Yes, yes I know, he's a total doofus. Anyway, they've been doing that ever since we even more intelligently designed anti...
Source: Stayin' Alive - March 15, 2013 Category: Health Medicine and Bioethics Commentators Source Type: blogs
March Diabetes News Snippet Post
Here are all the news items posted in March: Jennysaid... People taking Byetta, Victoza, Januvia, and Onglyza had less heart failure than those not on these drugs. http://www.sciencedaily.com/releases/2013/03/130310164109.htmHowever, it is likely this is because Avandia and Actos CAUSE heart failure, rather than that these other drugs prevent it. People are rarely put on both families of drugs at once. It may also be because these GLP-1 related drugs are mostly prescribed to affluent, younger people with diabetes and good health insurance, while poorer people are put on the cheap sulfonylurea drugs which are now known to r...
Source: Diabetes Update - March 11, 2013 Category: Diabetes Authors: Jenny Source Type: blogs
CBO Report: Improved Patient Adherence Benefits Medicare
Prescription medicines help people avoid the disability and death caused by disease, and help lower overall treatment costs. In fact, medical advances, including prescription medicines, have lowered death rates for heart disease, stroke, cancer, and other deadly diseases. Two years ago, a report from Eli Lilly noted how if it were not for the declines in death rates from heart disease and stroke, we would lose 1 million more Americans every year.
In addition, the 5-year survival rates for cancer have risen by 26% just since 1984. And while HIV/AIDS was the 8th leading cause of death in the US in 1996, today, it’...
Source: Policy and Medicine - February 20, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs
Shire to Forest on Deal List for AstraZeneca: Real M&A - Bloomberg
For AstraZeneca Plc to reverse its worst profit slide, the drugmaker needs to make its biggest purchase since at least 2007. AstraZeneca reported a 37 percent drop in 2012 earnings and forecast profit this year will decline “significantly more than revenue” after the $59 billion company suffered setbacks in developing new therapies to replace best-selling drugs that are losing patent protection. While Chief Executive Officer Pascal Soriot said he will focus on internal efforts and purchases of $3 billion to $4 billion to help boost the lowest valuations in the industry, Exane BNP Paribas said only a “transformational...
Source: PharmaGossip - February 12, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Lipitor & Plavix: The Last of the Small Molecule Best Sellers?
Forbes just published a list of "Best Selling Drugs of All Time" (see here). I created the following chart from the data cited (click on it for a larger view):"Tellingly," notes the Forbes author, Simon King, "each of the products in the list above best positioned to record an increase in peak annual sales over the next five years is a biologic; Humira, Enbrel, Rituxan, Herceptin and Lantus being the chief candidates. This is driven by a number of factors – the later launch of certain brands, for example – but also illustrates the robustness of leading biologic franchises that do not face direct substitutable generic c...
Source: Pharma Marketing Blog - January 28, 2013 Category: Pharma Commentators Tags: Drug prices Plavix Humira Lipitor Pfizer drug pipeline orphan drugs Blockbuster Source Type: blogs
Top stories in health and medicine, January 27, 2013
This series is brought to you by MedPage Today.1. Statins May Lower Death Risk in Liver Ca. Statin use seemed to reduce the risk of death in patients with hepatocellular cancer.2. FDA Panel Votes for Tighter Controls on Vicodin. An FDA advisory committee voted 19 to 10 on Friday in favor of moving hydrocodone combination drugs such as Vicodin, Lortab, and Norco into the more restrictive schedule II category of controlled substances.3. Chlorhexidine Baths in PICU Cut Infections. Scrubbing children in intensive care units with chlorhexidine daily cut the incidence of bacteremia by more than 35% in a randomized, crossover tri...
Source: Kevin, M.D. - Medical Weblog - January 28, 2013 Category: Family Physicians Tags: News GI Infectious disease Source Type: blogs
Time to Refill Your Prescription For Zxygjfb
The brand names of drugs are famously odd. But they seem to be getting odder. That's the conclusion of a longtime reader, who sent this along:
I was recently perusing through the recent drug approval list and was struck by how strange the trade names have become. Perhaps it is a request from the FDA so that there are fewer prescription errors, but some of these are really bizarre and don't quite roll off the tongue. USAN names I can understand, but trade names, to me anyway, used to be much more polished (Viagra, Lipitor etc). Could it have to do with the fact that most of these are for cancer? I have a list below compar...
Source: In the Pipeline - January 28, 2013 Category: Chemists Tags: Business and Markets Source Type: blogs
Pharma Deals North of $10 Billion Seen Returning in 2013 - Bloomberg
Get ready for the return of the $10 billion-plus drug deal. Pharmaceutical companies including Pfizer Inc. (PFE) and Bristol- Myers Squibb Co. (BMY) have spent the last several years digesting earlier acquisitions, refocusing their product development and setting aside cash in anticipation of expiring patents. Now, the expectation is they’re ready to start buying again. Led by Pfizer, in New York, and Whitehouse Station, New Jersey-based Merck & Co. (MRK), five of the largest U.S. drugmakers had more than $70 billion in cash, near cash and short-term investments at the end of the third quarter. ...
Source: PharmaGossip - January 7, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Some Interesting Pharma Predictions for 2013
It's appropriate that I present a few pharma industry predictions for 2013 in the last post of the year to Pharma Marketing Blog. To compile the following list, I used data from surveys, looked at the past year as an indication of what may be important in 2013, and reviewed predictions from the usual suspects (e.g., people in the #pharma100 list).It's also a good time to revisit a survey I started a couple of years ago that attempted to predict future healthcare market scenarios that would impact the drug industry. The survey asks respondents how likely it is for certain events or conditions to unfold ...
Source: Pharma Marketing Blog - December 31, 2012 Category: Pharma Commentators Tags: Apps predictions DTC Advertising social media marketing Sales and Sales Reps Mobile Advertising counterfeit medicine Source Type: blogs
